Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Schumacher HR Jr, et al. Among authors: joseph ridge n. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209. Arthritis Rheum. 2008. PMID: 18975369 Free article. Clinical Trial.
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Becker MA, et al. Arthritis Rheum. 2005 Mar;52(3):916-23. doi: 10.1002/art.20935. Arthritis Rheum. 2005. PMID: 15751090 Clinical Trial.
24 results